Kremer J, Bingham C, Cappelli L, et al. Post-appoval comparative safety study of tofacitinib and biological DMARDS: five-year results from a US-based rheumatoid arthritis registry. EULAR 2019; Madrid: Abstract OP0028.
Definiëren van renale remissie bij 248 patiënten met lupusnefritis
dec 2021 | Systemische lupus erythematodes